These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 25382392)

  • 1. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
    Venci JV; Gandhi MA
    Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
    Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
    Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
    Valencia-Sanchez C; Carter JL
    Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate : a Janus-faced substance?
    Kees F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1559-67. PubMed ID: 23697607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.
    Stangel M; Linker RA
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Meltzer L; Kurukulasuriya NC
    Mult Scler; 2015 Jan; 21(1):57-66. PubMed ID: 24990854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E; Hutchinson M; Kurukulasuriya NC; Raghupathi K; Sweetser MT; Dawson KT; Gold R
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl fumarate for relapsing-remitting multiple sclerosis.
    Drug Ther Bull; 2014 Sep; 52(9):105-8. PubMed ID: 25213591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
    Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
    Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate (Tecfidera) for multiple sclerosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
    Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of fumaric acid esters in psoriasis.
    Roll A; Reich K; Boer A
    Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.